Le Lézard
Classified in: Mining industry, Health, Business, Covid-19 virus
Subject: ACC

ICL Provides Business and Operational Update Related to the COVID-19 Pandemic


TEL AVIV, Israel, March 25, 2020 /PRNewswire/ -- The outbreak of the COVID-19 virus in China and its worldwide spread has caused significant volatility and uncertainty in global markets. Accordingly, there has been a decline in global economic activity, and there is concern that economic activity will continue to moderate in light of the prevention measures being taken by the various governments around the world. Given these conditions, ICL (NYSE: ICL) (TASE: ICL), (the Company) has taken actions to maintain the health of its employees, suppliers, business partners and the communities in which it operates as well as to continue the proper and regular functioning of its facilities around the world to minimize the potential impact on its business. Specifically:

The foregoing update includes forward-looking information, which is inherently uncertain. As of the date of this report, the Company is unable to accurately assess the impact of the COVID-19 virus pandemic on the Company, due to, among other factors, the heightened volatility in the markets, the uncertainty regarding the duration of the pandemic, the extent of its impact on the markets in which the Company operates, and additional countermeasures governments and central banks may take. For more details on the potential risks identified by the Company at this time, the Company refers to the risk factors as published in the Company's Annual Report for 2019, and in particular, to the risk factors for natural disasters and epidemics, including the COVID-19 virus pandemic; The risk to global demand and supply; Availability of credit lines and risk of crisis in global financial markets; Completing CAPEX projects and the challenges the Israeli Rotem phosphate operations is facing. In connection with the COVID-19 crisis, the Company identifies the risk of discontinuing the operations of its major potash and bromine plants in Israel as a result of widespread infection, as the most significant risk to its business in the near future. To the extent that any of the risks described above or any other risk specified in the Company's risk factors will be realized, and in particular if one of such Company's major plants ceases to operate, it may have an impact, and even have a material impact on the Company's business and results.

 

PRESS CONTACT     

Adi Bajayo

Scherf Communications

+972-52-4454789

[email protected]


INVESTOR RELATIONS CONTACT        

Dudi Musler

Investor Relations Manager

+972-3-6844448

[email protected]

SOURCE ICL


These press releases may also interest you

at 16:10
Boyd Gaming Corporation today reported financial results for the first quarter ended March 31, 2024. Keith Smith, President and Chief Executive Officer of Boyd Gaming, said: "After a record 2023, the first quarter of 2024 was a challenging start...

at 16:10
Finer detail and even greater precision are coming to Stratasys' SAFtm technology. Today, Stratasys announced its new SAFtm HighDef Printing capabilities and the launch of the H350tm printer, Version 1.5 (V.1.5) to expand SAF adoption with...

at 16:10
Carlisle Companies Incorporated today announced its first quarter 2024 financial results. Diluted EPS of $3.52 and adj. EPS of $3.72, an increase of 85% YoY Revenue of $1.1 billion, an increase of 23% YoY Operating margin of 20.5% and adj....

at 16:05
Data I/O Corporation , the leading global provider of advanced security and data deployment solutions for microcontrollers, security ICs and memory devices, today announced financial results for the first quarter ended March 31, 2024. First Quarter...

at 16:05
SkyWest, Inc. ("SkyWest") today reported financial and operating results for Q1 2024, including net income of $60 million, or $1.45 per diluted share, compared to net loss of $22 million, or $0.45 loss per share, for Q1 2023. Commenting on the...

at 16:05
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...



News published on and distributed by: